LT2575467T - Makrocikliniai junginiai naudojami kaip histonų deacetilazių inhibitoriai - Google Patents

Makrocikliniai junginiai naudojami kaip histonų deacetilazių inhibitoriai

Info

Publication number
LT2575467T
LT2575467T LTEP11787462.8T LT11787462T LT2575467T LT 2575467 T LT2575467 T LT 2575467T LT 11787462 T LT11787462 T LT 11787462T LT 2575467 T LT2575467 T LT 2575467T
Authority
LT
Lithuania
Prior art keywords
inhibitors
compounds useful
histone deacetylases
macrocyclic compounds
macrocyclic
Prior art date
Application number
LTEP11787462.8T
Other languages
English (en)
Inventor
Xuedong Liu
Andrew J. Phillips
Dana Ungermannova
Christopher G. Nasveschuk
Gan Zhang
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of LT2575467T publication Critical patent/LT2575467T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LTEP11787462.8T 2010-05-27 2011-05-26 Makrocikliniai junginiai naudojami kaip histonų deacetilazių inhibitoriai LT2575467T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34897810P 2010-05-27 2010-05-27
PCT/US2011/038246 WO2011150283A1 (en) 2010-05-27 2011-05-26 Macrocyclic compounds useful as inhibitors of histone deacetylases

Publications (1)

Publication Number Publication Date
LT2575467T true LT2575467T (lt) 2017-01-10

Family

ID=45004403

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11787462.8T LT2575467T (lt) 2010-05-27 2011-05-26 Makrocikliniai junginiai naudojami kaip histonų deacetilazių inhibitoriai

Country Status (18)

Country Link
US (2) US8754050B2 (lt)
EP (1) EP2575467B1 (lt)
JP (1) JP5931850B2 (lt)
KR (2) KR102028850B1 (lt)
CN (1) CN102946732B (lt)
AU (1) AU2011258110B2 (lt)
BR (1) BR112012030193B1 (lt)
CA (1) CA2800958C (lt)
DK (1) DK2575467T3 (lt)
ES (1) ES2594500T3 (lt)
HK (1) HK1181613A1 (lt)
HU (1) HUE030812T2 (lt)
LT (1) LT2575467T (lt)
MX (1) MX2012013507A (lt)
PL (1) PL2575467T3 (lt)
PT (1) PT2575467T (lt)
RU (1) RU2565076C2 (lt)
WO (1) WO2011150283A1 (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391359B (zh) * 2011-11-17 2014-07-16 南京优科生物医药研究有限公司 组蛋白去乙酰化酶抑制剂及其合成方法和制药用途
CN103232474A (zh) * 2013-04-16 2013-08-07 中国药科大学 组蛋白去乙酰化酶抑制剂
CN106800589B (zh) * 2013-09-02 2021-01-12 李铁旦 一类环肽类化合物、其制备方法、药物组合物及用途
DK3578179T3 (da) * 2014-05-27 2021-03-15 Onkure Inc Process for the preparation of cyclic depsipeptides
JP6785801B2 (ja) * 2015-03-06 2020-11-18 コロラド ステート ユニバーシティー リサーチ ファウンデーション 新しいキャップ基ラルガゾールの類似体の合成及び使用
CA2978698A1 (en) 2015-03-06 2016-09-15 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
CN105131082A (zh) * 2015-09-17 2015-12-09 广州康缔安生物科技有限公司 环肽类化合物及其应用
CN106674252B (zh) * 2015-11-11 2019-10-29 复旦大学 海洋天然产物环酯肽的氟代烯烃类似物、其制备方法和用途
JP6691958B2 (ja) * 2016-05-20 2020-05-13 オンキュアー，インコーポレイテッド ヒストンデアセチラーゼの阻害剤としての大環状分子のチオエステルプロドラッグ
CN107286223B (zh) * 2017-07-17 2019-12-20 湖北大学 一种用于检测组蛋白位点乙酰化的重组蛋白及其应用
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
US20220017520A1 (en) * 2018-12-19 2022-01-20 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
EP3941457A4 (en) 2019-03-21 2023-04-26 Merck Sharp & Dohme LLC HISTONE-DEACETYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
KR102436309B1 (ko) * 2020-05-26 2022-08-25 연세대학교 산학협력단 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920304D0 (en) 1989-09-08 1989-10-25 Fujisawa Pharmaceutical Co Fr901375 substance and preparation thereof
US7098186B2 (en) * 2002-08-30 2006-08-29 Astellas Pharma Inc Depsipeptide compound
KR20050074547A (ko) * 2002-11-12 2005-07-18 알콘, 인코퍼레이티드 눈의 퇴행성 질환을 치료하기 위한 히스톤 디아세틸라제저해제
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US8865655B2 (en) * 2006-11-22 2014-10-21 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
EP2276757B1 (en) * 2008-04-11 2016-01-06 University of Florida Research Foundation, Inc. Macrocyclic compounds and methods of treatment
US8217076B2 (en) * 2008-07-17 2012-07-10 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
CN102391359B (zh) * 2011-11-17 2014-07-16 南京优科生物医药研究有限公司 组蛋白去乙酰化酶抑制剂及其合成方法和制药用途

Also Published As

Publication number Publication date
US9422340B2 (en) 2016-08-23
WO2011150283A1 (en) 2011-12-01
AU2011258110A1 (en) 2013-01-10
EP2575467A1 (en) 2013-04-10
HUE030812T2 (en) 2017-05-29
US20130203681A1 (en) 2013-08-08
US20150010541A1 (en) 2015-01-08
CN102946732B (zh) 2014-11-26
MX2012013507A (es) 2013-03-12
PT2575467T (pt) 2016-10-14
BR112012030193B1 (pt) 2020-11-17
BR112012030193A2 (pt) 2015-09-29
AU2011258110B2 (en) 2015-07-16
KR102028850B1 (ko) 2019-10-04
CN102946732A (zh) 2013-02-27
CA2800958A1 (en) 2011-12-01
KR20130123301A (ko) 2013-11-12
ES2594500T3 (es) 2016-12-20
EP2575467B1 (en) 2016-07-06
RU2012157293A (ru) 2014-07-10
PL2575467T3 (pl) 2017-10-31
RU2565076C2 (ru) 2015-10-20
CA2800958C (en) 2018-09-04
HK1181613A1 (en) 2013-11-15
US8754050B2 (en) 2014-06-17
JP2013528182A (ja) 2013-07-08
KR20180081153A (ko) 2018-07-13
EP2575467A4 (en) 2014-10-15
DK2575467T3 (en) 2016-09-26
JP5931850B2 (ja) 2016-06-08

Similar Documents

Publication Publication Date Title
HK1259135A1 (zh) Vmat2的苯並喹啉酮抑制劑
HK1181613A1 (en) Macrocyclic compounds useful as inhibitors of histone deacetylases
ZA201707157B (en) Multisubsituted aromatic compounds as inhibitors of thrombin
ZA201700326B (en) Inhibitors of beta-secretase
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2701699A4 (en) INHIBITORS OF HISTONE DEACETYLASE
HK1176616A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6 cdk4/6
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
EP2584903A4 (en) NEW HETEROCYCLIC COMPOUNDS AS ERK HEMMER
PT2566930T (pt) Uso de composições para refrigeração
EP2539348A4 (en) CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE
ZA201206456B (en) Uses of dgati inhibitors
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
ZA201208895B (en) Bicyclic compound derivatives and their use as acc inhibitors
SG2014013460A (en) Monohydrate of an azaadamantane derivative
IL222313A0 (en) Combination of organic compounds
EP2531197A4 (en) SOLID FORMS OF MACROCYCLIC CHINESE INHIBITORS
EP2579872A4 (en) HAMMER OF ACT ACTIVITY
IL225708A0 (en) Methods for the synthesis of scylitol and related compounds
GB2492717B (en) Detecting no progress state of an application
EP2543373A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
HK1160443A1 (en) Histone deacetylase inhibitors
GB201010671D0 (en) Compounds for treatment of inflammation